Pemgarda
Payments companies reported to CMS as associated with Pemgarda. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Pemgarda, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Pemgarda
These are the largest totals companies reported as associated with Pemgarda. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Paul Bolno | Stowe, VT | $134,351.00 | |
| Robert Gottlieb | Dallas, TX | Advanced Heart Failure and Transplant Cardiology | $16,789.57 |
| Cedric Spak | Fort Worth, TX | Infectious Disease | $13,341.69 |
| Teena Chopra | Detroit, MI | Infectious Disease | $10,800.00 |
| Muhammad Bilal Abid | Milwaukee, WI | Hospitalist | $9,313.75 |
| Roy Chemaly | Houston, TX | Infectious Disease | $8,797.98 |
| Amesh Adalja | Pittsburgh, PA | Infectious Disease | $6,715.60 |
| George Yaghmour | Los Angeles, CA | Hematology & Oncology | $4,427.50 |
| Imran Iqbal | Dallas, TX | $4,340.60 | |
| Rajat Walia | Phoenix, AZ | Pulmonary Disease | $4,009.40 |
Prescribed Pemgarda?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.